Stay updated with breaking news from Nasdaq Abos. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS – Get Free Report) was the recipient of a large decrease in short interest during the month of April. As of April 15th, there was short interest totalling 1,050,000 shares, a decrease of 15.3% from the March 31st total of 1,240,000 shares. Based on an average daily volume of 341,300 shares, […]
Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS – Get Free Report) was the target of a significant growth in short interest in January. As of January 15th, there was short interest totalling 699,400 shares, a growth of 53.6% from the December 31st total of 455,200 shares. Approximately 1.8% of the company’s stock are short sold. Based on an […]
Commodore Capital LP reduced its stake in shares of Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS – Free Report) by 19.7% during the 1st quarter, according to its most recent 13F filing with the SEC. The firm owned 400,000 shares of the company’s stock after selling 98,315 shares during the period. Commodore Capital LP owned approximately 0.98% of […]
Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS – Get Free Report) Director Jeffrey L. Ives sold 41,949 shares of the stock in a transaction on Thursday, August 17th. The stock was sold at an average price of $6.49, for a total value of $272,249.01. The sale was disclosed in a legal filing with the Securities & Exchange Commission, […]
CHARLOTTESVILLE, Va. and CARMEL, Ind., July 18, 2023 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (“Acumen”) (NASDAQ: ABOS), a clinical-stage...